Yan Leyfman, Co-Founder and Executive Director of MedNews Week, shared a post on X about a recent article by Takashi Kadowaki et al. published in JAMA Internal Medicine:
“OASIS 2 Trial: Oral Semaglutide in East Asian Populations
In a 68-week RCT of 201 East Asian adults with overweight/obesity (±T2D), oral semaglutide 50 mg led to:
- 14.3% avg weight loss vs. −1.3% with placebo
- 84% achieved ≥5% weight reduction (vs. 17% placebo)
- Improvements in cardiometabolic risk factors
- Safety profile consistent with GLP-1RA class
- GI side effects were common but led to low discontinuation (4.5%)
- Conducted across Japan and South Korea
Takeaway: Oral semaglutide may offer a potent weight management tool in East Asian patients, where obesity-related risk occurs at lower BMIs.”
Title: Oral Semaglutide in an East Asian Population With Overweight or Obesity, With or Without Type 2 Diabetes
Authors: Takashi Kadowaki, Line Dam Heftdal, Hae-Jin Ko
Read the Full Article on JAMA Internal Medicine
More posts featuring Yan Leyfman.